NovoCure (NVCR) to Release Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $172.7180 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.The business had revenue of $174.06 million during the quarter, compared to analysts’ expectations of $167.77 million. During the same period last year, the company earned ($0.31) earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NovoCure Stock Up 3.1%

Shares of NovoCure stock opened at $16.03 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.90 and a quick ratio of 2.70. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -10.48 and a beta of 0.94. The firm’s 50-day moving average is $16.79 and its two-hundred day moving average is $13.97. NovoCure has a 1 year low of $9.82 and a 1 year high of $18.92.

Analysts Set New Price Targets

NVCR has been the subject of several research reports. Wedbush reaffirmed a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a research report on Thursday, April 16th. JPMorgan Chase & Co. began coverage on NovoCure in a research report on Monday. They set a “neutral” rating and a $17.00 target price on the stock. Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. HC Wainwright reissued a “buy” rating and issued a $46.00 price target (down from $48.00) on shares of NovoCure in a research report on Thursday, June 18th. Finally, Wells Fargo & Company upped their price objective on NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.60.

Insider Buying and Selling at NovoCure

In other news, Director W Anthony Vernon sold 2,945 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director directly owned 197,657 shares in the company, valued at $3,117,050.89. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director owned 13,861 shares in the company, valued at approximately $218,587.97. This represents a 17.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is owned by corporate insiders.

Institutional Trading of NovoCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVCR. Corient Private Wealth LLC raised its stake in shares of NovoCure by 178.0% during the 4th quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after buying an additional 62,341 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in NovoCure by 14.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock valued at $422,000 after acquiring an additional 4,124 shares during the period. Empowered Funds LLC purchased a new stake in NovoCure in the 4th quarter worth $33,000. XTX Topco Ltd increased its holdings in NovoCure by 159.2% in the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 36,111 shares in the last quarter. Finally, Vestal Point Capital LP raised its position in NovoCure by 31.2% during the fourth quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock worth $6,788,000 after acquiring an additional 125,000 shares during the period. Institutional investors and hedge funds own 84.61% of the company’s stock.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.